GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
Robert J WatsonPaul BamboroughHeather BarnettChun-Wa ChungRob DavisLaurie GordonPaola GrandiMassimo PetretichAlex PhillipouRab K PrinjhaInmaculada RiojaPeter SodenThilo WernerEmmanuel H DemontPublished in: Journal of medicinal chemistry (2020)
Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins. They have shown profound efficacy in vitro and in vivo in oncology and immunomodulatory models, and a number of them are currently in clinical trials where significant safety signals have been reported. It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity. This article discloses the in vitro and cellular activity profiles of GSK789, a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.